Severe Phenotype in Patients with Large Deletions of NF1

Simple Summary Neurofibromatosis type 1 (NF1) is a genetic disorder caused by pathogenic variants in the NF1 tumor suppressor gene. In 5–10% of NF1 patients, a large heterozygous deletion of the whole NF1 gene is identified, leading to the commonly called “NF1 microdeletion syndrome”. NF1-deleted patients were previously reported to develop a particularly severe form of the disease with frequent cognitive impairment and an increased risk of benign and malignant tumors. Here, we performed a comprehensive clinical assessment of the largest NF1-deleted cohort to date, including 126 NF1 patients with a deletion of the NF1 gene. This work provides new insights into the specific phenotype associated with NF1 deletions and may contribute to improve the follow-up care of NF1 patients. Abstract Complete deletion of the NF1 gene is identified in 5–10% of patients with neurofibromatosis type 1 (NF1). Several studies have previously described particularly severe forms of the disease in NF1 patients with deletion of the NF1 locus, but comprehensive descriptions of large cohorts are still missing to fully characterize this contiguous gene syndrome. NF1-deleted patients were enrolled and phenotypically characterized with a standardized questionnaire between 2005 and 2020 from a large French NF1 cohort. Statistical analyses for main NF1-associated symptoms were performed versus an NF1 reference population. A deletion of the NF1 gene was detected in 4% (139/3479) of molecularly confirmed NF1 index cases. The median age of the group at clinical investigations was 21 years old. A comprehensive clinical assessment showed that 93% (116/126) of NF1-deleted patients fulfilled the NIH criteria for NF1. More than half had café-au-lait spots, skinfold freckling, Lisch nodules, neurofibromas, neurological abnormalities, and cognitive impairment or learning disabilities. Comparison with previously described “classic” NF1 cohorts showed a significantly higher proportion of symptomatic spinal neurofibromas, dysmorphism, learning disabilities, malignancies, and skeletal and cardiovascular abnormalities in the NF1-deleted group. We described the largest NF1-deleted cohort to date and clarified the more severe phenotype observed in these patients.

[1]  L. Kluwe,et al.  Genotype-phenotype correlation in neurofibromatosis type-1: NF1 whole gene deletions lead to high tumor-burden and increased tumor-growth , 2021, PLoS genetics.

[2]  K. Ross,et al.  suz12 inactivation in p53- and nf1-deficient zebrafish accelerates the onset of malignant peripheral nerve sheath tumors and expands the spectrum of tumor types , 2020, Disease Models & Mechanisms.

[3]  C. Assaiante,et al.  Are morphological and structural MRI characteristics related to specific cognitive impairments in neurofibromatosis type 1 (NF1) children? , 2020, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[4]  C. Indolfi,et al.  Functional and morphological cardiovascular alterations associated with neurofibromatosis 1 , 2020, Scientific Reports.

[5]  P. Lapunzina,et al.  Co‐occurrence of neurofibromatosis type 1 and optic nerve gliomas with autosomal dominant polycystic kidney disease type 2 , 2020, Molecular genetics & genomic medicine.

[6]  A. Bayat,et al.  Neurological manifestations of neurofibromatosis: a review , 2020, Neurological Sciences.

[7]  S. Steinberg,et al.  Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: Growth analysis of plexiform neurofibromas and distinct nodular lesions. , 2020, Neuro-oncology.

[8]  B. Korf,et al.  An Update on Neurofibromatosis Type 1-Associated Gliomas , 2020, Cancers.

[9]  Eun Key Kim,et al.  Phenotype categorization of neurofibromatosis type I and correlation to NF1 mutation types , 2019, Journal of Human Genetics.

[10]  G. Finocchiaro,et al.  Risk of Optic Pathway Glioma in Neurofibromatosis Type 1: No Evidence of Genotype–Phenotype Correlations in a Large Independent Cohort , 2019, Cancers.

[11]  Michael F. Wangler,et al.  Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype–phenotype study in neurofibromatosis type 1 , 2019, Human mutation.

[12]  D. Gutmann,et al.  Brain tumors in neurofibromatosis type 1 , 2019, Neuro-oncology advances.

[13]  M. Digilio,et al.  Prevalence, Type, and Molecular Spectrum of NF1 Mutations in Patients with Neurofibromatosis Type 1 and Congenital Heart Disease , 2019, Genes.

[14]  D. Gutmann,et al.  Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1 , 2019, Journal of neuroscience research.

[15]  D. Baralle,et al.  Breast cancer risk in neurofibromatosis type 1 is a function of the type of NF1 gene mutation: a new genotype-phenotype correlation , 2018, Journal of Medical Genetics.

[16]  Michael F. Wangler,et al.  Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype–phenotype correlation , 2018, Genetics in Medicine.

[17]  T. Hershey,et al.  Increased prevalence of brain tumors classified as T2 hyperintensities in neurofibromatosis 1 , 2018, Neurology. Clinical practice.

[18]  B. Korf,et al.  Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study , 2018, Orphanet Journal of Rare Diseases.

[19]  E. Zackai,et al.  Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844–848 , 2017, American journal of human genetics.

[20]  M. Kinori,et al.  Ophthalmic manifestations in neurofibromatosis type 1. , 2017, Survey of ophthalmology.

[21]  A. Vélez van Meerbeke,et al.  Cognitive and Behavioral Disorders in Children with Neurofibromatosis Type 1 , 2017, Front. Pediatr..

[22]  A. Cacchione,et al.  Growth hormone excess in children with neurofibromatosis type‐1 and optic glioma , 2017, American journal of medical genetics. Part A.

[23]  D. Bianchessi,et al.  Identification of an atypical microdeletion generating the RNF135-SUZ12 chimeric gene and causing a position effect in an NF1 patient with overgrowth , 2017, Human Genetics.

[24]  I. Laurendeau,et al.  Confirmation of mutation landscape of NF1‐associated malignant peripheral nerve sheath tumors , 2017, Genes, chromosomes & cancer.

[25]  Kimberly J. Johnson,et al.  Neurofibromatosis type 1 , 2017, Nature Reviews Disease Primers.

[26]  D. Cooper,et al.  Emerging genotype–phenotype relationships in patients with large NF1 deletions , 2017, Human Genetics.

[27]  S. Perreault,et al.  Café-au-lait Macules and Neurofibromatosis Type 1: A Review of the Literature. , 2016, Pediatric neurology.

[28]  H. Kehrer-Sawatzki,et al.  Growth in neurofibromatosis 1 microdeletion patients , 2016, Clinical genetics.

[29]  Ying Liu,et al.  High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotype–Phenotype Correlation , 2015, Human mutation.

[30]  M. Peschanski,et al.  In vitro modeling of hyperpigmentation associated to neurofibromatosis type 1 using melanocytes derived from human embryonic stem cells , 2015, Proceedings of the National Academy of Sciences.

[31]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[32]  C. Bizzarri,et al.  Endocrine Implications of Neurofibromatosis 1 in Childhood , 2015, Hormone Research in Paediatrics.

[33]  H. Blanché,et al.  NF1 single and multi-exons copy number variations in neurofibromatosis type 1 , 2015, Journal of Human Genetics.

[34]  R. Margraf,et al.  Evaluation of somatic mutations in tibial pseudarthrosis samples in neurofibromatosis type 1 , 2015, Journal of Medical Genetics.

[35]  M. Digilio,et al.  p.Arg1809Cys substitution in neurofibromin is associated with a distinctive NF1 phenotype without neurofibromas , 2014, European Journal of Human Genetics.

[36]  Eric Legius,et al.  PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies , 2014, Nature.

[37]  E. Pasmant,et al.  Neurofibromatosis type 1 molecular diagnosis: what can NGS do for you when you have a large gene with loss of function mutations? , 2014, European Journal of Human Genetics.

[38]  M. Vihinen,et al.  Novel association of neurofibromatosis type 1‐causing mutations in families with neurofibromatosis‐noonan syndrome , 2014, American journal of medical genetics. Part A.

[39]  H. Blanché,et al.  NF1 Molecular Characterization and Neurofibromatosis Type I Genotype–Phenotype Correlation: The French Experience , 2013, Human mutation.

[40]  D. O. Onu,et al.  Charcot-Marie-Tooth syndrome and neurofibromatosis type 1 with multiple neurofibromas of the entire spinal nerve roots , 2013, BMJ Case Reports.

[41]  M. Goldacre,et al.  Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage study , 2012, British Journal of Cancer.

[42]  G. Stacy,et al.  Musculoskeletal manifestations of neurofibromatosis type 1. , 2012, AJR. American journal of roentgenology.

[43]  D. Cooper,et al.  Neurofibromatosis type 1-associated tumours: Their somatic mutational spectrum and pathogenesis , 2011, Human Genomics.

[44]  J. Lefaucheur,et al.  At-Risk Phenotype of Neurofibromatose-1 Patients: A Multicentre Case-Control Study , 2011, Orphanet journal of rare diseases.

[45]  K. Shah The diagnostic and clinical significance of café-au-lait macules. , 2010, Pediatric clinics of North America.

[46]  D. Cooper,et al.  Clinical characterisation of 29 neurofibromatosis type-1 patients with molecularly ascertained 1.4 Mb type-1 NF1 deletions , 2010, Journal of Medical Genetics.

[47]  M. Sanson,et al.  NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype , 2010, Human mutation.

[48]  T. Pietsch,et al.  Natural history and management of low-grade glioma in NF-1 children , 2010, Journal of Neuro-Oncology.

[49]  S. Ekvall,et al.  Noonan syndrome and neurofibromatosis type I in a family with a novel mutation in NF1 , 2009, Clinical genetics.

[50]  J. Soulier,et al.  Technical Advance Detection and Characterization of NF1 Microdeletions by Custom High Resolution Array CGH , 2009 .

[51]  E. Pasmant,et al.  Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1. , 2009, Human molecular genetics.

[52]  A. Guzel,et al.  Neurofibromatosis type 1 associated with Charcot–Marie–Tooth type 1A , 2009, The Journal of dermatology.

[53]  Michael A Babcock,et al.  Neurofibromatosis Type 1 Revisited , 2009, Pediatrics.

[54]  N. Thomas,et al.  Germline and somatic NF1 gene mutations in plexiform neurofibromas , 2008, Human mutation.

[55]  I. Bièche,et al.  Characterization of a 7.6-Mb germline deletion encompassing the NF1 locus and about a hundred genes in an NF1 contiguous gene syndrome patient , 2008, European Journal of Human Genetics.

[56]  J. Zeller,et al.  Association between benign and malignant peripheral nerve sheath tumors in NF1 , 2005, Neurology.

[57]  J. Lambert,et al.  Pigment cell-related manifestations in neurofibromatosis type 1: an overview. , 2005, Pigment cell research.

[58]  R. Siebert,et al.  Screening 500 unselected neurofibromatosis 1 patients for deletions of the NF1 gene , 2004, Human mutation.

[59]  D. Cooper,et al.  Evaluation of genotype-phenotype correlations in neurofibromatosis type 1 , 2003, Journal of medical genetics.

[60]  J. Friedman,et al.  Analysis of intrafamilial phenotypic variation in neurofibromatosis 1 (NF1) , 2002, Genetic epidemiology.

[61]  C. Romano,et al.  Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1. , 2000, American journal of medical genetics.

[62]  G Mortier,et al.  Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects , 2000, Human mutation.

[63]  J. Friedman,et al.  Growth charts for young children with neurofibromatosis 1 (NF1) , 2000, American journal of medical genetics.

[64]  R. Tenconi,et al.  Neurofibromatosis type 1 growth charts. , 1999, American journal of medical genetics.

[65]  M Super,et al.  A clinical study of type 1 neurofibromatosis in north west England , 1999, Journal of medical genetics.

[66]  J. Carey,et al.  Neurofibromatosis-Noonan syndrome. , 1998, American journal of medical genetics.

[67]  X. Estivill,et al.  Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. , 1997, American journal of human genetics.

[68]  A. Deimling,et al.  Neurofibromatosis Type 1: Pathology, Clinical Features and Molecular Genetics , 1995, Brain pathology.

[69]  D. Easton,et al.  An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. , 1993, American journal of human genetics.

[70]  Margaret Robertson,et al.  The neurofibromatosis type 1 gene encodes a protein related to GAP , 1990, Cell.

[71]  S. Huson,et al.  A genetic study of von Recklinghausen neurofibromatosis in south east Wales. II. Guidelines for genetic counselling. , 1989, Journal of medical genetics.

[72]  S. Huson,et al.  Ophthalmic manifestations of neurofibromatosis. , 1987, The British journal of ophthalmology.

[73]  D. Gutmann,et al.  Optic Pathway Gliomas in Neurofibromatosis Type 1 , 2018, Journal of child neurology.

[74]  E. Haan,et al.  An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation. , 2007, American journal of human genetics.

[75]  J. Dietemann,et al.  [Imaging features of neurofibromatosis type 1]. , 2005, Journal of neuroradiology. Journal de neuroradiologie.

[76]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[77]  J. Lupski,et al.  Stable inheritance of the CMT1A DNA duplication in two patients with CMT1 and NF1. , 1993, American journal of medical genetics.

[78]  D. Dunn,et al.  Neurofibromatosis, Charcot-Marie-Tooth disease, or both? , 1989, Neurofibromatosis.

[79]  National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987. , 1988, Neurofibromatosis.